T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Vishal Navani,Matthew Scott Ernst,J. Connor Wells,Takeshi Yuasa,Kosuke Takemura,Frede Donskov,Naveen S. Basappa,Andrew Schmidt,Sumanta K. Pal,Luis Meza,Lori Wood,D. S. Ernst,Bernadett Szabados,Thomas Powles,Rana R. McKay,Andrew Weickhardt,Cristina Sáez,Anil Kapoor,Jae-Lyun Lee,Toni K. Choueiri,Daniel Y.C. Heng +20 more
TL;DR: Objective imaging response was associated with improvement in overall survival among patients receiving both types of therapy and combination therapies with first-line immune checkpoint blockade plus vascular endothelial growth factor receptor inhibitor were more likely to be associated with objective imaging response.
Journal ArticleDOI
Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes.
Journal ArticleDOI
Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
TL;DR: The outcome of patients with stage I nonseminomatous germ cell tumors (NSGCTs) is excellent, with 99% overall 5-year survival, but adjuvant therapy with either chemotherapy or retroperitoneal lymph node dissection (RPLND) is often recommended, despite impressive results with active surveillance alone.
Journal ArticleDOI
Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.
Pedro C. Barata,Alfonso Gomez de Liano,Prateek Mendiratta,Valerie Crolley,Bernadett Szabados,Laura S. Wood,Beth R. Zanick,Kimberly D Allman,Allison Janine Tyler,Allison Martin,Timothy D. Gilligan,Petros Grivas,Moshe Chaim Ornstein,Jorge A. Garcia,Thomas Powles,Brian I. Rini +15 more
TL;DR: A retrospective analysis of all pts with clear-cell mRCC enrolled in one of seven clinical trials investigating an IO-COMBO at Cleveland Clinic Taussig Cancer Institute and Barts Cancer Institute found 32 pts with PD who received ≥1 line of subsequent therapy, including best objective response according to RECIST v1.1.
Journal ArticleDOI
IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
Thomas Powles,David F. McDermott,Brian I. Rini,Robert J. Motzer,Michael B. Atkins,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,Alain Ravaud,Sergio Bracarda,C. Suarez Rodriguez,Michele Maio,M. E. Gore,Viktor Grünwald,Michael Staehler,Jiaheng Qiu,Alpa Thobhani,Mahrukh Huseni,Christina Schiff,Bernard Escudier +19 more